GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » Short Percentage of Float

OncoCyte (STU:7OC0) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of OncoCyte's Short Percentage of Float

For the Diagnostics & Research subindustry, OncoCyte's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoCyte's Short Percentage of Float Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where OncoCyte's Short Percentage of Float falls into.


OncoCyte (STU:7OC0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » Short Percentage of Float
Comparable Companies
CHEK TTOO TRIB PMD STRR XGN BIAF PRPO APDN LMDX TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
OCX:USA
Address
15 Cushing, Irvine, CA, USA, 92618
Website
https://www.oncocyte.com
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (STU:7OC0) Headlines

No Headlines